USC.edu
Are You a Patient?

David Tran, MD, PhD

Associate Professor of Neurological Surgery and Neurology

Division Chief, Neuro-Oncology (Neurological Surgery) and Co-Director of the USC Brain Tumor Center (BTC)

Image of David Tran, MD, PhD
Websites
Is this your profile? Click to edit
Request an Appointment
Email [email protected]
CTSI Profile

Overview

Dr Tran received his MD and PhD degrees from the Mayo Clinic College of Medicine in 2005 and completed his postgraduate training in Oncology and Neuro-Oncology at Washington University School of Medicine in St Louis in 2011. He is a leader in Precision Medicine with many seminal publications in cancer research and serves as the principal investigator of several national clinical trials in brain cancer. Research in the Tran laboratory focuses on understanding the molecular mechanism of how cancer develops, progresses, and resists treatment through a vertically integrated approach, starting with clinical observations, guided by systems and computational analyses, followed by experimental validation and translation into novel anti-cancer therapeutics.

Research Funding

  • Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
    NIH · R01CA238387 · Jun 15, 2020 – May 31, 2026 · Role: Principal Investigator
  • Targeting glioblastoma stem-like cells with custom-designed viral vectors
    NIH · R42CA228875 · Apr 16, 2018 – Aug 31, 2021 · Role: Co-Principal Investigator
  • Role of Twist1 in EMT Maintenance and tumor dormancy
    NIH · K08CA160824 · Aug 1, 2013 – Jul 31, 2018 · Role: Principal Investigator

Publications

  • Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. Neuro Oncol. 2018 03 27; 20(4):472-483.. View in PubMed
  • Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. J Neurooncol. 2018 May; 138(1):105-111.. View in PubMed
  • Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 12 19; 318(23):2306-2316.. View in PubMed
  • Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors’ reply. Lancet Oncol. 2017 12; 18(12):e709-e710.. View in PubMed
  • Eleven Month Progression-Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic BRAF V600E-Mutated Glioblastoma WHO Grade 4. JCO Precis Oncol. 2017 Nov; 1:1-5.. View in PubMed
  • Machine Learning of Human Pluripotent Stem Cell-Derived Engineered Cardiac Tissue Contractility for Automated Drug Classification. Stem Cell Reports. 2017 11 14; 9(5):1560-1572.. View in PubMed
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 10; 18(10):1373-1385.. View in PubMed
  • An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc Natl Acad Sci U S A. 2016 12 20; 113(51):E8247-E8256.. View in PubMed
  • Molecular and histologic characteristics of pseudoprogression in diffuse gliomas. J Neurooncol. 2016 12; 130(3):529-533.. View in PubMed
  • A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. J Neurooncol. 2016 06; 128(2):259-66.. View in PubMed

Similar People